Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.89 USD | -6.86% | -7.91% | -27.77% |
Jun. 03 | UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment | MT |
Jun. 03 | UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 3.75 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.77% | 255M | B- | ||
+18.15% | 124B | B+ | ||
+18.02% | 111B | B+ | ||
-12.75% | 23.17B | B+ | ||
+5.07% | 22.94B | B | ||
-39.94% | 17.42B | A- | ||
-9.86% | 17.42B | B | ||
-14.97% | 16.9B | A- | ||
+2.80% | 13.71B | C+ | ||
+27.39% | 11.82B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QURE Stock
- Ratings uniQure N.V.